Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

NCT01353027 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Ebola Hemorrhagic Fever

Interventions

DRUG: Placebo
DRUG: AVI-6002

Sponsor

Sarepta Therapeutics, Inc.

Collaborators

[object Object]